Search

A 36-year-old woman experienced neutropenia while being treated with aciclovir for varicella-zoster virus (VZV) infection. She also showed lack of efficacy during treatment with edaravone, argatroban, aspirin, and clopidogrel for bilateral medial medullary infarction. Despite receiving these therapies, her symptoms worsened. After further evaluation, she was diagnosed with VZV vasculopathy and received treatment with aciclovir and prednisone pulse therapy. However, she developed neutropenia due to the aciclovir therapy and her treatment was discontinued. She was eventually transferred to another hospital for rehabilitation after 70 days of hospitalization. [Extracted from the article]

A case report published in Reactions Weekly describes a 62-year-old woman who developed disseminated herpes zoster infection while being treated with abrocitinib for severe atopic dermatitis. The woman initially presented with worsening leg pain and subsequently experienced persistent pain, ulcerated lesions, and periorbital edema. Skin swabs confirmed a varicella zoster virus infection, leading to a diagnosis of disseminated herpes zoster infection secondary to abrocitinib. The woman was started on unspecified antiviral therapy to treat the infection. [Extracted from the article]

Two case reports describe women who developed varicella zoster virus (VZV) infections while being treated with upadacitinib for different conditions. The first patient, a 35-year-old woman with atopic dermatitis, experienced pain and skin changes in her right mandible and cheek. She was diagnosed with VZV infection and treated with antiviral medication. The second patient, an 80-year-old woman with presumed hypereosinophilic syndrome, developed ulcers on her forearm and back. She was also diagnosed with VZV infection and recovered after treatment. Both patients had different outcomes and were managed accordingly. [Extracted from the article]

A 52-year-old woman developed progressive multifocal leukoencephalopathy (PML) due to a John Cunningham (JC) virus infection while undergoing immunosuppressant treatment for systemic sclerosis. She also did not respond to treatment with ganciclovir for the JC virus. The woman experienced various symptoms, including behavioral disturbances, decreased visuospatial orientation, and left hemiparesis. After stopping mycophenolate mofetil and continuing with a low dose of methylprednisolone, she received off-label treatment with IV immune-globulin, which slightly improved her communication and decreased apathy. A diagnosis of PML was confirmed through a positive PCR report for JC virus DNA in the cerebrospinal fluid. The woman then received ganciclovir for JC virus infection, but due to a worsening of symptoms and lack of efficacy, she was discharged and continued to receive IV immune-globulin infusions every month. Her condition significantly improved, with her MMSE score, visual acuity, and behavior returning to normal. [Extracted from the article]

A 16-year-old girl experienced a lack of efficacy after receiving the varicella-zoster-virus vaccine against the herpes zoster virus. Despite being fully vaccinated against the varicella zoster virus at the ages of 1 and 6, she presented with a skin rash that was diagnosed as chickenpox through a positive polymerase chain reaction (PCR) test. The girl was treated with valaciclovir for 7 days, and her symptoms completely disappeared after the treatment. [Extracted from the article]

A retrospective case series involving 16 patients at the MS Research Center of Sina and Qaem hospital found that three patients developed chickenpox and headache while being treated with natalizumab for multiple sclerosis. The first patient, a 27-year-old woman, developed self-limited chickenpox and discontinued natalizumab due to a high JC virus index. The second patient, a 16-year-old man, also developed mild chickenpox but continued natalizumab and received a varicella-zoster virus vaccine. The third patient, a 43-year-old man, experienced mild headache and continued natalizumab, eventually receiving the varicella-zoster virus vaccine. [Extracted from the article]

A 42-year-old woman with connective tissue disease overlap syndrome-related interstitial lung disease developed varicella zoster virus (VZV) meningoencephalitis while being treated with mycophenolate and prednisone. She also experienced a lack of efficacy during treatment with aciclovir for VZV meningoencephalitis. The woman received a shingles vaccine in January 2023 and presented to the hospital in April 2023 with symptoms including headache, seizure, altered mental status, gait deviation, and urinary incontinence. She underwent various tests and was treated with IV aciclovir for 14 days, but subsequent MRI and CSF analysis showed persistent abnormalities, indicating a lack of efficacy to aciclovir. She was then treated with valaciclovir for recurrent VZV meningoencephalitis. [Extracted from the article]

A 65-year-old man developed disseminated herpes zoster, or shingles, after receiving the tozinameran COVID-19 vaccine. He presented with a rash all over his body a week after receiving the third dose of the vaccine. Tests confirmed the presence of the varicella-zoster virus, which causes shingles. The man was treated with aciclovir and eventually recovered. The Naranjo scale indicated a probable causal relationship between the vaccine and the development of shingles. [Extracted from the article]

A retrospective cohort study described five patients who developed ocular infections caused by the Varicella-zoster (VZV) and Herpes-Simplex (HSV) viruses after receiving the tozinameran COVID-19 vaccine. The patients, aged 48-81 years, experienced various symptoms such as blurred vision, vesicular rashes, and conjunctival infections. They were diagnosed with VZV ophthalmicus, VZV anterior uveitis, VZV keratouveitis and vitritis, HSV blepharoconjunctivitis, or HSV1 keratouveitis. Treatment with antiviral medications and corticosteroids led to resolution of symptoms in all cases. [Extracted from the article]

A 60-year-old man developed Cytomegalovirus (CMV) infection and Varicella zoster virus (VZV) meningoencephalitis while undergoing immunosuppression therapy following a kidney transplant. The man experienced pain, vesicular lesions, and other symptoms before being admitted to the hospital. Tests confirmed the presence of CMV and VZV, and it was determined that the immunosuppression therapy made him more susceptible to these viral infections. After discontinuing the immunosuppression therapy and receiving treatment, the man experienced a complete recovery and was discharged from the hospital after two months. [Extracted from the article]

A 39-year-old woman experienced erythema nodosum (EN) and varicella-zoster virus (VZV) reactivation after receiving the elasomeran COVID-19 vaccine. She developed painful rashes on her lower legs and erythematous skin lesions on her thighs after receiving the vaccine. Histopathological findings confirmed the diagnosis of EN and VZV reactivation, which was attributed to the vaccine. The woman was treated with potassium iodide and her symptoms gradually improved. [Extracted from the article]

A 39-year-old woman experienced erythema nodosum (EN) and varicella-zoster virus (VZV) reactivation after receiving the elasomeran COVID-19 vaccine. She developed painful rashes on her lower legs and erythematous skin lesions on her thighs after receiving the vaccine. Histopathological findings confirmed the diagnosis of EN and VZV reactivation, which were attributed to the vaccine. The woman was treated with potassium iodide, and her symptoms gradually improved. [Extracted from the article]

A 33-year-old woman with antiphospholipid antibody syndrome and systemic lupus erythematosus (SLAE) experienced a recurrent varicella zoster virus (VZV) infection while undergoing immunosuppressive treatment with prednisolone, mycophenolate-mofetil, and tacrolimus. She presented with painful purpura and bullae, and laboratory tests revealed low white blood cell count. Histopathological findings indicated the presence of VZV or herpes simplex virus (HSV). Treatment with valacyclovir was successful, and the patient was diagnosed with recurrent VZV infection caused by the immunosuppressive treatment. [Extracted from the article]

A 33-year-old woman with antiphospholipid antibody syndrome and systemic lupus erythematosus (SLAE) experienced a recurrent varicella zoster virus (VZV) infection while undergoing immunosuppressive treatment with prednisolone, mycophenolate-mofetil, and tacrolimus. She presented with painful purpura and bullae, and laboratory tests revealed low white blood cell count. Histopathological findings indicated the presence of VZV or herpes simplex virus (HSV). Treatment with valacyclovir was successful, and the patient was diagnosed with recurrent VZV infection caused by the immunosuppressive treatment. [Extracted from the article]

A retrospective cohort study conducted at a French University Hospital examined the occurrence of various infections in 121 patients treated with rituximab, a medication used for autoimmune diseases. The study identified 26 patients who developed infections such as pneumonia, pyelonephritis, colitis, and viral infections like Herpes simplex and Varicella zoster. Some patients required intensive care, and two patients died due to complications from the infections. The study highlights the potential risk of infections associated with rituximab therapy, emphasizing the importance of monitoring and appropriate management. [Extracted from the article]

A case report in the journal Reactions Weekly describes a 43-year-old woman who experienced a lack of efficacy when treated with naproxen for a severe headache. The woman had a medical history of anxiety, childhood chickenpox, and being 18 months post-partum. She presented to the emergency department with a headache, photophobia, and other symptoms suggestive of meningitis. After further testing, she was diagnosed with varicella-zoster virus (VZV) meningitis and treated with acyclovir. Her symptoms gradually resolved and she was discharged without complications. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 49-year-old-woman developed Varicella zoster virus (VZV) infection and cytomegalovirus (CMV) reactivation during treatment with prednisolone, mycophenolate-mofetil and hydroxychloroquine for systemic lupus erythematosus (SLE) [routes and time to reactions onset not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA man exhibited lack of efficacy during treatment with infliximab, vedolizumab and ustekinumab for ulcerative colitis [age at onest not stated]. Additionally, he developed shingles during treatment with tofacitinib for ulcerative colitis and exhibited a vaccine failure following administration of GSK-137173A at the age of 48 years [routes not stated; not all dosages and durations of treatments to reactions onset stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventAn adult woman [exact age not stated] developed cerebral varicella zoster virus (VZV) vasculopathy during treatment with natalizumab for multiple sclerosis (MS). Additionally, the woman exhibited lack of efficacy during treatment with interferon-beta-1a and dimethyl-fumarate for MS [dosages and routes not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 20-month-old girl developed reactivation of varicella zoster vaccine virus following vaccination with varicella zoster virus vaccine live and off-label treatment with dexamethasone for COVID-19 [routes not stated; not all dosages and times to reaction onset stated]. [Extracted from the article]

A retrospective cohort study of 31 heart transplantation recipients found that they developed rashes after receiving the varicella-zoster-virus-vaccine-live for immunization against varicella zoster virus infection. The rashes appeared 12-30 days after vaccination and lasted for 1-7 days. The rashes were described as red spots, fluid-filled spots, or macular spots on various parts of the body. It was concluded that the rashes were a result of the vaccine. [Extracted from the article]

An 18-month-old girl developed meningoencephalitis after receiving the MMR-varicella-zoster-virus vaccine. The girl had a primitive neuroectodermal tumor and was undergoing treatment, including chemotherapy and stem cell transplantations. After receiving the vaccine, she developed papulovesicular lesions on her hand, which were positive for varicella zoster virus (VZV). She was treated with aciclovir and foscarnet, and her neurological status improved within five days. She recovered from meningoencephalitis without any neurological complications. [Extracted from the article]

This article presents a retrospective study of six patients with adult-onset Still's disease (AOSD) or systemic-onset juvenile idiopathic arthritis (SJIA) who were treated with Janus kinase inhibitors (JAKi). Two patients developed organized pneumonia or Varicella-zoster virus infection during treatment with ruxolitinib, while four patients experienced treatment failure with baricitinib or tofacitinib. The article provides specific cases of patients who experienced these adverse events or lack of efficacy with the medications. It concludes that further research is needed to better understand the risks and benefits of JAKi treatment for AOSD and SJIA. [Extracted from the article]

A 55-year-old man with type 2 diabetes, HIV, and herpes zoster experienced a lack of efficacy while being treated with aciclovir for varicella zoster virus (VZV) vasculopathy. He was admitted to the hospital with symptoms including high fever, headache, and consciousness disorder. Despite receiving aciclovir, his condition worsened, as evidenced by MRI results and deterioration of neurological symptoms. As a result, the man was switched to valacyclovir and prednisone for VZV vasculopathy and abacavir/dolutegravir/lamivudine for HIV. [Extracted from the article]

A 52-year-old man developed disseminated Herpes Zoster with Zoster pneumonitis and Varicella zoster virus (VZV) infection during immunosuppressive therapy with mycophenolate, ciclosporin, and ruxolitinib. The man had a history of chickenpox and myelodysplastic syndrome and required an allogenic stem cell transplant. He presented to the emergency department with a body rash, which quickly spread and became intensely itchy. He also experienced respiratory symptoms and was diagnosed with disseminated Herpes Zoster with Zoster pneumonitis. Treatment with aciclovir was successful, and the patient remained off-immunosuppressive therapy for four months before starting a new medication. The case suggests a possible link between the immunosuppressive drugs and the development of the infection. [Extracted from the article]

A 45-year-old woman experienced a recurrent varicella zoster virus infection after receiving the SARS-COV-2-vaccine-inactivated-Sinovac-Biotech for COVID-19. She developed multiple pruritic vesicles and erythema on her head, neck, and trunk. The woman had a history of varicella in childhood and received the second dose of the vaccine three days before the appearance of symptoms. Reflectance confocal microscopy confirmed the diagnosis of recurrent varicella, and the infection was attributed to the vaccine. The woman was treated with famciclovir, and her lesions resolved after 10 days. [Extracted from the article]

An 89-year-old man with a history of various medical conditions, including orbital myositis, was treated with prednisolone but did not experience any improvement in his symptoms. In fact, his condition worsened, leading to the discovery of an underlying Varicella Zoster Virus (VZV) infection and confirmed infectious orbital myositis. Tragically, the man experienced neurological deterioration and ultimately passed away after 20 days of hospitalization. The specific cause of death was not mentioned in the article. [Extracted from the article]

A 70-year-old man with rheumatoid arthritis developed granulomatous dermatitis due to chronic varicella-zoster virus (VZV) infection while being treated with methotrexate, prednisone, and rituximab. The man had nonhealing ulcers on his right lower abdomen and left hand, which were in the same area where he had a VZV infection two years prior. Biopsies confirmed the diagnosis of granulomatous dermatitis due to chronic VZV infection. Treatment with valaciclovir resulted in significant healing and resolution of the ulcers. [Extracted from the article]

An 11-year-old boy experienced various complications during treatment for herpes zoster (HZ). He developed lymphopenia and lack of efficacy while taking aciclovir, and also experienced HZ ophthalmicus and HZ meningoencephalitis. Despite receiving the varicella zoster virus vaccine, he still developed these conditions, indicating vaccine failure. The boy's lymphocyte levels returned to normal six months later, and testing confirmed the presence of the vaccine strain in his cerebrospinal fluid. [Extracted from the article]

A safety summary of vaccinations in Canada during 2022 found no new safety concerns, according to Health Canada. The report analyzed 402 reports of adverse events following immunization (AEFIs), excluding those related to COVID-19 vaccines. The majority of AEFI reports were in adults over 18 years old, with the most common vaccines involved being varicella zoster virus, influenza, and pneumococcal vaccines. Most of the reported serious AEFIs were associated with herpes zoster and influenza vaccines, with symptoms including infection, vaccination failure, pain, cough, and fever. Health Canada emphasized that the benefits of authorized vaccines in Canada outweigh the risks and will continue to monitor their safety. [Extracted from the article]

Among them, two women received BBIBP-CorV [Sinopharm (Vero Cell)-inactivated COVID-19 vaccination], one woman received SARS-COV-2-vaccine-inactivated-Sinovac-Biotech [Sinovac COVID-19 Vaccine (Vero Cell), Inactivated], two women received BBIBP-CorV [Sinopharm/WIBP] and one woman received ZF-2001 [Zhifei Longcom SARS-CoV-2 inactivated vaccine]. Additionally, one patient exhibited vaccination failure following VZV immunisation with I Varicella zoster i virus vaccine [ I routes and dosages not stated; not all duration of treatments to reactions onset stated i ]. [Extracted from the article]

CSF examination revealed 13 cells/µL, mononuclear cells 12 cells/µL, 66.1 mg/dL protein, and blood glucose was 121 mg/dL. Aseptic meningitis after amenamevir treatment for herpes zoster ophthalmicus with oculomotor nerve palsy in a patient taking immunosuppressant. Her HZ ophthalmicus, oculomotor nerve palsy and aseptic meningitis occurred due to the delayed VZV clearance. [Extracted from the article]

Her right eye IOP was 16 mm[Hg] and in the left eye was 18 mm[Hg]. Examination revealed a best corrected visual acuity (BCVA) was counting fingers in the right eye and 6/6 in the left eye. Right eye fundus examination was normal. [Extracted from the article]